IMJUDO vs SORAFENIB TOSYLATE

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated June 7, 2026·How we rate

Possible drug interaction. IMJUDO and SORAFENIB TOSYLATE are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	IMJUDO	SORAFENIB TOSYLATE
Rating	New	New
Pharmacy pays	—	—
Type	RX	RX
Active ingredient	TREMELIMUMAB-ACTL	SORAFENIB TOSYLATE
Manufacturer	Astrazeneca Ab	Yabao Pharm
Dosage forms	Injectable	Tablet
Drug class	—	Kinase Inhibitor
Boxed warning	None	None
Treats	Hepatocellular Carcinoma	Renal Cell Carcinoma, Hepatocellular Carcinoma, Thyroid Neoplasms

imjudo sorafenib tosylate

Rating

New

Pharmacy pays

—

Type

Active ingredient

TREMELIMUMAB-ACTL

SORAFENIB TOSYLATE

Manufacturer

Astrazeneca Ab

Yabao Pharm

Dosage forms

Injectable

Tablet

Drug class

—

Kinase Inhibitor

Boxed warning

None

Treats

Hepatocellular Carcinoma

Renal Cell Carcinoma, Hepatocellular Carcinoma, Thyroid Neoplasms

Frequently asked questions

What is the difference between Imjudo and Sorafenib Tosylate?

Imjudo contains Tremelimumab-Actl, while Sorafenib Tosylate contains Sorafenib Tosylate — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.